Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 3	OCT 19	BEILSTEIN updated with new compounds
NEWS 4	NOV 15	Derwent Indian patent publication number format enhanced
NEWS 5	NOV 19	WPIX enhanced with XML display format
NEWS 6	NOV 30	ICSD reloaded with enhancements
NEWS 7	DEC 04	LINPADOCDB now available on STN
NEWS 8	DEC 14	BEILSTEIN pricing structure to change
NEWS 9	DEC 17	USPATOLD added to additional database clusters
NEWS 10	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS 11	DEC 17	DGENE now includes more than 10 million sequences
NEWS 12	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 13	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 14	DEC 17	CA/CAplus enhanced with new custom IPC display formats
NEWS 15	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS 16	JAN 02	STN pricing information for 2008 now available
NEWS 17	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 18	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 19	JAN 28	MARPAT searching enhanced
NEWS 20	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS 21	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 22	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS 23	FEB 08	STN Express, Version 8.3, now available
NEWS 24	FEB 20	PCI now available as a replacement to DPCI
NEWS 25	FEB 25	IFIREF reloaded with enhancements
NEWS 26	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS 27	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:49:22 ON 18 MAR 2008

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:49:32 ON 18 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 MAR 2008 HIGHEST RN 1008496-49-8
DICTIONARY FILE UPDATES: 17 MAR 2008 HIGHEST RN 1008496-49-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10586765.str



```
chain nodes :
10
ring nodes :
1  2  3  4  5  6  11  12  13  14  15  18  19  20  21  22  23
ring/chain nodes :
7  8  9
chain bonds :
9-10  9-11  14-18
ring/chain bonds :
1-7  7-8  8-9
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  11-12  11-15  12-13  13-14  14-15  18-19  18-23
19-20  20-21  21-22  22-23
exact/norm bonds :
1-7  7-8  8-9  9-10  13-14  14-18  18-19  18-23  19-20  20-21  21-22  22-23
exact bonds :
9-11  11-12  11-15  12-13  14-15
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6
isolated ring systems :
containing 11 :


G1:C,H,O,Cl,Br,F,OH,Cy,S,N

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:CLASS
 11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  18:Atom  19:Atom  20:Atom  21:Atom
22:Atom  23:Atom



L1      STRUCTURE UPLOADED

=> d 11
L1 HAS NO ANSWERS
L1              STR
```



G1 C,H,O,Cl,Br,F,CH,Cy,S,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 12:49:50 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     5599 TO ITERATE

 35.7% PROCESSED     2000 ITERATIONS                                1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
PROJECTED ITERATIONS:       107494 TO   116466
PROJECTED ANSWERS:               1 TO      155

L2            1 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 12:49:53 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   109276 TO ITERATE

100.0% PROCESSED   109276 ITERATIONS                            104 ANSWERS
SEARCH TIME: 00.00.01

L3          104 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   178.36     178.57

FILE 'CAPLUS' ENTERED AT 12:49:57 ON 18 MAR 2008
```

FILE COVERS 1907 - 18 Mar 2008 VOL 148 ISS 12
FILE LAST UPDATED: 17 Mar 2008 (20080317/ED)

=> s l3 full
L4 7 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:301787 CAPLUS

DOCUMENT NUMBER: 144:350698

TITLE: Preparation of benzoxazine derivatives as modulators of chemokine receptors for treatment of inflammation and immunoregulatory diseases

INVENTOR(S): Goble, Stephen D.; Mills, Sander G.; Yang, Lihu; Pasternak, Alexander; Bonnefous, Celine; Kamenecka, Theodore M.; Vernier, Jean-Michel; Hutchinson, John H.; Hu, Essa; Govek, Steven

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 94 pp., Cont.-in-part of Appl. No. PCT/US04/011281.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006069088	A1	20060330	US 2005-129512	20050513
WO 2004092124	A2	20041028	WO 2004-US11281	20040408
WO 2004092124	A3	20050414		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-463111P P 20030415
WO 2004-US11281 A2 20040408

OTHER SOURCE(S): MARPAT 144:350698

GI



I



II

AB Title benzoxazine derivs. I [wherein X = C, N, O, or S; Y = O, S, SO, SO2, or (un)substituted NH; Z = C or N; R1 = H, (un)substituted alkoxy(alkyl), alkylthio(alkyl), heterocyclyloxy(alkyl), etc.; R2 = halo, (un)substituted alkyl, alkoxy(alkyl), alkylthio(alkyl), etc.; R3 = H, (un)substituted phenyl(alkyl), cycloalkyl(alkyl), heterocyclyl(alkyl), etc.; R4 = OH, CN, alkoxyl, etc.; R5 and R6 = independently H, OH, halo, alkyl, alkoxyl, etc.; when Z = C, R7 = H, OH, halo, (un)substituted alkyl, alkoxy, etc.; when Z = N, R7 is nothing or oxide; R8 = H, alkyl, CF3, OCF3, halo, etc.; m and n = independently 0-2 wherein m + n = 0-3], or pharmaceutically acceptable salts or diastereomers thereof were prepared as modulators of CCR2 chemokine receptors. For example, II was prepared in a multi-step synthesis. The title compds. are useful as modulators of CCR-2 chemokine receptors for the prevention or treatment of inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis (no data).

IT 881493-17-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of benzoxazine derivs. as modulators of chemokine receptors for treatment of inflammatory and immunoregulatory diseases)

RN 881493-17-0 CAPLUS

CN Benzoic acid, 3-[1-[(1R,3S)-3-(1-methylethyl)-3-[[6-(trifluoromethyl)-2H-pyrido[3,2-e]-1,3-oxazin-3(4H)-yl]carbonyl]cyclopentyl]-4-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:696675 CAPLUS
DOCUMENT NUMBER: 143:193909
TITLE: Preparation of 2,6-disubstituted piperidines as modulators of chemokine receptors
INVENTOR(S): Yang, Lihu; Mills, Sander G.; Zhou, Changyou; Goble, Stephen D.; Pasternak, Alexander
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005070133	A2	20050804	WO 2005-US770	20050114
WO 2005070133	A3	20050901		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005206791	A1	20050804	AU 2005-206791	20050114
CA 2553242	A1	20050804	CA 2005-2553242	20050114
EP 1732552	A2	20061220	EP 2005-711338	20050114
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, LV				
CN 1909906	A	20070207	CN 2005-80002715	20050114
JP 2007518799	T	20070712	JP 2006-551125	20050114
IN 2006DN03835	A	20070427	IN 2006-DN3835	20060704
US 2007179158	A1	20070802	US 2006-586765	20060720
PRIORITY APPLN. INFO.:			US 2004-537732P P	20040120
			WO 2005-US770 W	20050114

OTHER SOURCE(S): CASREACT 143:193909; MARPAT 143:193909
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = H, OH, CN, etc.; R2 = H, (un)substituted alkyl or alkoxy; R3 = H, halo, OH, etc. when Y is C or R3 is oxygen or absent when Y is N; R4 = H, trifluoromethyl, trifluoromethoxy, etc.; R5 = (un)substituted alkyl, alkoxy, thioalkyl, etc.; R6 = H, alkyl, chloro, etc.; R7 = nothing when X is O, S, or SO2 or R7 = H, alkylphenyl, alkylheterocycle, etc. when X is C or N; R8 = H, OH, alkyl, etc. when X is C or R8 = nothing when X is O, S, SO2, etc. or R7 and R8 together form a ring selected from (un)substituted 1H-indene, 2,3-dihydro-1H-indene, 2,3-dihydro-benzofuran, etc.; R9 and R10 independently = H, OH, alkyl, etc. or R7 and R9, or R8 and R10 together form (un)substituted Ph or heterocycle; R11, R13, R14 and R15 independently = H, OH, alkyl, etc.; R12 and R16 independently = OH, (un)substituted alkoxy, alkylhydroxy, etc. or R12 and R16 together form a bridge consisting of (un)substituted alkyl or

alkyl-O-alkyl; R17 = H, (un)substituted Ph or alkyl or R2 and R17 together form a heterocycle; Q = (CH2)n; X = C, N, O, etc.; Y = N or C; Z = (CH2)0-1; n = 0-2] and their pharmaceutically acceptable salts, are prepared and disclosed as modulators of chemokine receptors. Thus, e.g., II was prepared by Grignard reaction of N-carbethoxy-4-tropinone with Ph magnesium bromide followed by dehydration/hydrogenation/decarboxylation sequence and subsequent coupling with III (preparation given). The binding activity of I towards the CCR-2 receptor was evaluated and it was revealed that compds. of the invention are useful modulators of chemokine receptor activity (data given). I as modulator of chemokine receptors should prove useful in the treatment of rheumatoid arthritis. Pharmaceutical compns. comprising I are disclosed.

IT 861853-56-7P 861855-43-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2,6-disubstituted piperidines as modulators of chemokine receptors)

RN 861853-56-7 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[1-(1-methylethyl)-3-(3-phenyl-8-azabicyclo[3.2.1]oct-8-yl)cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)





RN 861855-43-8 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-1-(1-methylethyl)-3-[(3-exo)-3-[3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:141023 CAPLUS
DOCUMENT NUMBER: 142:240424
TITLE: Preparation of (thiazolyl)cyclopentane amide modulators of chemokine receptor activity
INVENTOR(S): Butora, Gabor; Yang, Lihu; Goble, Stephen D.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005014537	A2	20050217	WO 2004-US25467	20040806
WO 2005014537	A3	20050512		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004263509	A1	20050217	AU 2004-263509	20040806
CA 2534294	A1	20050217	CA 2004-2534294	20040806
EP 1654256	A2	20060510	EP 2004-780322	20040806
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1832943	A	20060913	CN 2004-80022756	20040806
JP 2007501795	T	20070201	JP 2006-522756	20040806
IN 2006DN00519	A	20070810	IN 2006-DN519	20060131
US 2006205783	A1	20060914	US 2006-567516	20060207

PRIORITY APPLN. INFO.: US 2003-493902P P 20030808
WO 2004-US25467 W 20040806
OTHER SOURCE(S): CASREACT 142:240424; MARPAT 142:240424
GI



I



II

AB Title compds. I [wherein Z = independently C or N; R1 = (alkoxy)alkyl, alkylthioalkyl, hydroxy, etc.; R2-R4, R6 = independently H, OH, alkyl, halo, etc.; R5 = (carbonyl)alkyl, CF3, halo, etc.; R7, R9 = independently H, Ph, alkyl, etc.; R8 = H, Ph, alkyl, etc.; R10 = (un)substituted tetrahydropyranyl-4-ylamino, azacyclohept-1-yl, azacyclooct-1-yl; and pharmaceutically acceptable salts or solvates thereof and individual diastereomers thereof] are prepd as chemokine receptor modulators (no data). For example, II was given in a multi-step synthesis starting from 2,6-dichloro-4-trifluoromethylpyridine. The invention is directed to pharmaceutical comps. comprising these compds. and the use of these compds. and comps. as chemokine receptor modulators in the prevention or treatment of the diseases in which chemokine receptors are involved, such as inflammatory and immunoregulatory disorders, and rheumatoid arthritis (no data).

IT 844639-97-0P 844639-99-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-pyridinylmethyl (thiazolyl)cyclopentane amide modulators of chemokine receptor activity)

RN 844639-97-0 CAPLUS
CN Carbamic acid, [4-[3-(hexahydro-1H-azepin-1-yl)-1-[[[[5-(trifluoromethyl)-3-pyridinyl]methyl]amino]carbonyl]cyclopentyl]-2-thiazolyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 844639-99-2 CAPLUS
CN Cyclopentanecarboxamide, 1-(2-amino-4-thiazolyl)-3-(hexahydro-1H-azepin-1-yl)-N-[[5-(trifluoromethyl)-3-pyridinyl]methyl]- (CA INDEX NAME)



L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:1124588 CAPLUS
DOCUMENT NUMBER: 142:69197
TITLE: CCR-2 antagonists for treatment of neuropathic pain
INVENTOR(S): Abbadie, Catherine; Lindia, Jill Ann; Wang, Hao
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 304 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004110376	A2	20041223	WO 2004-US17499	20040602
WO 2004110376	A3	20050224		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2006205761	A1	20060914	US 2005-559701	20051206
PRIORITY APPLN. INFO.:			US 2003-476391P P	20030606
			US 2003-531637P P	20031222
			WO 2004-US17499 W	20040602

OTHER SOURCE(S): MARPAT 142:69197
AB The invention is directed to methods of treating neuropathic pain and other neuropathic diseases and conditions with CCR-2 antagonists and pharmaceutical composition containing CCR-2 antagonists.
IT 766513-14-8P 766513-16-0P 766513-18-2P
766513-20-6P 766513-22-8P 766513-24-0P
767332-04-7P 767332-05-8P 767332-06-9P
767332-07-0P 767332-08-1P 767332-09-2P
787638-91-9P 787638-92-0P 787638-93-1P
787638-94-2P 787638-95-3P 787638-96-4P
787638-97-5P 787638-98-6P 787639-19-4P
787639-25-2P 787639-26-3P 787639-27-4P
787639-28-5P 787639-87-6P 787639-88-7P
787639-89-8P 787639-90-1P 787639-91-2P
787639-92-3P 787639-93-4P 787639-94-5P
787639-95-6P 787639-96-7P 787639-97-8P
787639-98-9P 791067-33-9P 791067-36-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(CCR2 antagonists for treatment of neuropathic pain)
RN 766513-14-8 CAPLUS
CN Cyclobutanecarboxamide, 1-(1-methylethyl)-3-(4-phenyl-1-piperidinyl)-N-[[5-(trifluoromethyl)-3-pyridinyl]methyl]- (CA INDEX NAME)



RN 766513-16-0 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[1-(1-methylethyl)-3-(4-phenyl-1-piperidinyl)cyclobutyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 766513-18-2 CAPLUS
CN Cyclobutanecarboxamide, 1-(1-hydroxyethyl)-3-(4-phenyl-1-piperidinyl)-N-[[5-(trifluoromethyl)-3-pyridinyl]methyl]- (CA INDEX NAME)



RN 766513-20-6 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[1-(1-hydroxyethyl)-3-(4-phenyl-1-piperidinyl)cyclobutyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 766513-22-8 CAPLUS
CN Cyclobutanecarboxamide, 1-(1-hydroxy-1-methylethyl)-3-(4-phenyl-1-

piperidinyl)-N-[[5-(trifluoromethyl)-3-pyridinyl]methyl]- (CA INDEX NAME)



RN 766513-24-0 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[1-(1-hydroxy-1-methylethyl)-3-(4-phenyl-1-piperidinyl)cyclobutyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 767332-04-7 CAPLUS
CN Cyclobutanecarboxamide, 1-(1-methylethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-N-[[5-(trifluoromethyl)-3-pyridinyl]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 767332-05-8 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[1-(1-methylethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]cyclobutyl]carbonyl]-3-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 767332-06-9 CAPLUS
CN Cyclobutanecarboxamide, 1-(1-hydroxyethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-N-[[5-(trifluoromethyl)-3-pyridinyl]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 767332-07-0 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[1-(1-hydroxyethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]cyclobutyl]carbonyl]-3-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 767332-08-1 CAPLUS
CN Cyclobutanecarboxamide, 1-(1-hydroxy-1-methylethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-N-[[5-(trifluoromethyl)-3-pyridinyl]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 767332-09-2 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[1-(1-hydroxy-1-methylethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]cyclobutyl]carbonyl]-3-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 787638-91-9 CAPLUS
CN 4-Piperidinecarboxamide, 1-[(3S)-3-[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 787638-92-0 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[(3S)-3-[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 787638-93-1 CAPLUS
CN 3-Piperidinecarboxylic acid, 1-[(3S)-3-[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 787638-94-2 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-1-(1-methylethyl)-3-(4-methyl-1-piperidinyl)cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787638-95-3 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-1-(1-methylethyl)-3-(3-methyl-1-piperidinyl)cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787638-96-4 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-3-(3-hydroxy-1-piperidinyl)-1-(1-methylethyl)cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787638-97-5 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-3-(4-hydroxy-1-piperidinyl)-1-(1-methylethyl)cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787638-98-6 CAPLUS
CN 1,6-Naphthyridine, 6-[[(1S)-3-(1R,4S)-2-azabicyclo[2.2.1]hept-2-yl-1-(1-methylethyl)cyclopentyl]carbonyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-19-4 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-1-(1-methylethyl)-3-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylcyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-25-2 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-1-(1-methylethyl)-3-[3-(4-pyridinyl)-1-pyrrolidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-26-3 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-1-(1-methylethyl)-3-[3-(3-pyridinyl)-1-pyrrolidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-27-4 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-1-(1-methylethyl)-3-[3-(2-pyridinyl)-1-pyrrolidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-28-5 CAPLUS
CN 3-Pyrrolidineacetic acid, 1-[(3S)-3-[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-87-6 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-1-(1-methylethyl)-3-[4-(5-pyrimidinyl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-88-7 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-1-(1-methylethyl)-3-[4-(1H-tetrazol-1-yl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-89-8 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-1-(1-methylethyl)-3-[4-(1H-pyrazol-1-yl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-90-1 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-1-(1-methylethyl)-3-[4-(1H-1,2,3-triazol-1-yl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-91-2 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-1-(1-methylethyl)-3-[4-(1H-1,2,4-triazol-1-yl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-92-3 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-1-(1-methylethyl)-3-[4-(3H-pyrazol-3-yl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-93-4 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-1-(1-methylethyl)-3-[4-(5-methyl-2H-tetrazol-2-yl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-94-5 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-1-(1-methylethyl)-3-[4-(4-thiazolyl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-95-6 CAPLUS
CN Benzoic acid, 3-[1-[(3S)-3-[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]-4-piperidinyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-96-7 CAPLUS
CN Benzoic acid, 3-[1-[(3S)-3-[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]-4-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-97-8 CAPLUS
CN 1,6-Naphthyridine, 6-[[(1S)-3-[4-(2,5-dihydro-5-oxo-1,2,4-thiadiazol-3-yl)-1-piperidinyl]-1-(1-methylethyl)cyclopentyl]carbonyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-98-9 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-1-(1-methylethyl)-3-[3-(4-methyl-4H-1,2,4-triazol-3-yl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 791067-33-9 CAPLUS
CN 1,6-Naphthyridine, 6-[[(1S)-3-(3,5-dimethyl-1-piperidinyl)-1-(1-methylethyl)cyclopentyl]carbonyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 791067-36-2 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-1-(1-methylethyl)-3-[(4R,7S)-octahydro-4-methyl-4,7-epoxy-2H-isoindol-2-yl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:927165 CAPLUS
DOCUMENT NUMBER: 141:410822
TITLE: Preparation of heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity
INVENTOR(S): Butora, Gabor; Goble, Stephen D.; Pasternak, Alexander; Yang, Lihu; Zhou, Changyou; Moyes, Christopher R.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Merck Sharp & Dohme Limited
SOURCE: PCT Int. Appl., 187 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004094371	A2	20041104	WO 2004-US11463	20040414
WO 2004094371	A3	20050324		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004232939	A1	20041104	AU 2004-232939	20040414
CA 2521625	A1	20041104	CA 2004-2521625	20040414
EP 1622916	A2	20060208	EP 2004-750112	20040414
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1805965	A	20060719	CN 2004-80016537	20040414
JP 2006523704	T	20061019	JP 2006-510018	20040414
IN 2005DN04610	A	20071019	IN 2005-DN4610	20051010

PRIORITY APPLN. INFO.: US 2003-463673P P 20030417
WO 2004-US11463 W 20040414

OTHER SOURCE(S): MARPAT 141:410822
GI



I



II

AB Title compds. I [X = C. N, O, S, SO2; Y = N, C; R1 = H, alkyl, etc.; R2 = H, OH, halo, alkyl, amino, etc.; R3 = O or absent when Y = N and when Y = C, H, OH, halo, etc.; R4 = H, alkyl, CF3, etc.; R5 = alkyl, alkoxy, etc.; R6 = H, alkyl, CF3, etc.; R7 = H, (alkyl)phenyl, (alkyl)heterocycle, etc.; R8 = H, nothing when X = O, S, SO2, etc.; R9-10 = H, OH, alkyl, etc.; n = 0-2] are prepared For instance, II is prepared in several steps from 7-trifluoromethyl-1,2,3,4-tetrahydroisoquinoline (preparation given), Me 3-oxocyclopentanecarboxylate and 4-carboethoxypiperidine. I are modulators of the chemokine receptor CCR-2.

IT 787638-99-7P 787639-00-3P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity)

RN 787638-99-7 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[(1S,3S)-3-[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 787639-00-3 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[(1R,3S)-3-[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

IT 787639-04-7P 787639-05-8P 787639-06-9P
787639-07-0P 787639-08-1P 787639-09-2P
787639-10-5P 787639-11-6P 787639-12-7P
787639-13-8P 787639-14-9P 787639-15-0P
787639-22-9P 787639-23-0P 787639-82-1P

787639-83-2P 787639-85-4P 787639-86-5P
787640-61-3P 787640-62-4P 791067-35-1P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity)

RN 787639-04-7 CAPLUS

CN 4-Piperidinecarboxamide, 1-[(1S,3S)-3-[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 787639-05-8 CAPLUS

CN 4-Piperidinecarboxamide, 1-[(1R,3S)-3-[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 787639-06-9 CAPLUS
CN 3-Piperidinecarboxylic acid, 1-[(1S,3S)-3-[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 787639-07-0 CAPLUS
CN 3-Piperidinecarboxylic acid, 1-[(1R,3S)-3-[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 787639-08-1 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S,3S)-1-(1-methylethyl)-3-[(3R)-3-methyl-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 787639-09-2 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S,3S)-1-(1-methylethyl)-3-[(3S)-3-methyl-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 787639-10-5 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S,3R)-1-(1-methylethyl)-3-[(3S)-3-methyl-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 787639-11-6 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S,3R)-1-(1-methylethyl)-3-[(3R)-3-methyl-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 787639-12-7 CAPLUS
CN 1,6-Naphthyridine, 6-[[(1S,3R)-3-[(3S,5R)-3,5-dimethyl-1-piperidinyl]-1-(1-methylethyl)cyclopentyl]carbonyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 787639-13-8 CAPLUS
CN 1,6-Naphthyridine, 6-[[(1S,3S)-3-[(3S,5R)-3,5-dimethyl-1-piperidinyl]-1-(1-methylethyl)cyclopentyl]carbonyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 787639-14-9 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S,3S)-3-(4-hydroxy-1-piperidinyl)-1-(1-methylethyl)cyclopentyl]carbonyl]-3-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 787639-15-0 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S,3R)-3-(4-hydroxy-1-piperidinyl)-1-(1-methylethyl)cyclopentyl]carbonyl]-3-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 787639-22-9 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S,3S)-1-(1-methylethyl)-3-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylcyclopentyl]carbonyl]-3-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 787639-23-0 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S,3R)-1-(1-methylethyl)-3-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylcyclopentyl]carbonyl]-3-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 787639-82-1 CAPLUS
CN 1,6-Naphthyridine, 6-[[(1S,3S)-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)cyclopentyl]carbonyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-83-2 CAPLUS
CN 1,6-Naphthyridine, 6-[[(1S,3R)-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)cyclopentyl]carbonyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-85-4 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S,3R)-1-(1-methylethyl)-3-[4-(5-pyrimidinyl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-86-5 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S,3S)-1-(1-methylethyl)-3-[4-(5-pyrimidinyl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787640-61-3 CAPLUS
CN 1,6-Naphthyridine, 6-[[(1S,3R)-3-[(3R,5R)-3,5-dimethyl-1-piperidinyl]-1-(1-methylethyl)cyclopentyl]carbonyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 787640-62-4 CAPLUS
CN 1,6-Naphthyridine, 6-[[(1S,3S)-3-[(3R,5R)-3,5-dimethyl-1-piperidinyl]-1-(1-methylethyl)cyclopentyl]carbonyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 791067-35-1 CAPLUS
CN 1,6-Naphthyridine, 6-[[(1S)-3-(3,5-dimethyl-1-piperidinyl)-1-(1-methylethyl)cyclopentyl]carbonyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

IT 787638-91-9P 787638-93-1P 787638-95-3P
787639-19-4P 787639-84-3P 791067-33-9P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of heterocyclic cyclopentyl tetrahydroisoquinoline and

tetrahydropyridopyridine modulators of chemokine receptor activity)

RN 787638-91-9 CAPLUS

CN 4-Piperidinecarboxamide, 1-[(3S)-3-[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 787638-93-1 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[(3S)-3-[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 787638-95-3 CAPLUS

CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-1-(1-methylethyl)-3-(3-methyl-1-piperidinyl)cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-19-4 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-1-(1-methylethyl)-3-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylcyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-84-3 CAPLUS
CN 1,6-Naphthyridine, 6-[[(1S)-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(1-methylethyl)cyclopentyl]carbonyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 791067-33-9 CAPLUS
CN 1,6-Naphthyridine, 6-[[(1S)-3-(3,5-dimethyl-1-piperidinyl)-1-(1-methylethyl)cyclopentyl]carbonyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 787638-88-4P 787638-89-5P 787638-90-8P
787638-92-0P 787638-94-2P 787638-96-4P
787638-97-5P 787638-98-6P 787639-01-4P
787639-02-5P 787639-03-6P 787639-24-1P
787639-25-2P 787639-26-3P 787639-27-4P
787639-28-5P 787639-87-6P 787639-88-7P
787639-89-8P 787639-90-1P 787639-91-2P
787639-92-3P 787639-93-4P 787639-94-5P
787639-95-6P 787639-96-7P 787639-97-8P
787639-98-9P 787639-99-0P 787640-00-0P
787640-01-1P 787640-02-2P 787640-54-4P
791067-36-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity)

RN 787638-88-4 CAPLUS
CN 1,6-Naphthyridine, 6-[[3-(4-benzoyl-1-piperidinyl)-1-(1-methylethyl)cyclopentyl]carbonyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)



RN 787638-89-5 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[1-(1-methylethyl)-3-(1-oxo-2,8-diazaspiro[4.5]dec-8-yl)cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 787638-90-8 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-1-(1-methylethyl)-3-(1-piperidinyl)cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787638-92-0 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[(3S)-3-[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 787638-94-2 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-1-(1-methylethyl)-3-(4-methyl-1-piperidinyl)cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787638-96-4 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-3-(3-hydroxy-1-piperidinyl)-1-(1-methylethyl)cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787638-97-5 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-3-(4-hydroxy-1-piperidinyl)-1-(1-methylethyl)cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787638-98-6 CAPLUS
CN 1,6-Naphthyridine, 6-[[(1S)-3-(1R,4S)-2-azabicyclo[2.2.1]hept-2-yl-1-(1-methylethyl)cyclopentyl]carbonyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-01-4 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[(1S,3S)-3-[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 787639-02-5 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[(1R,3S)-3-[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-03-6 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S,3R)-3-[4-(hydroxymethyl)-1-piperidinyl]-1-(1-methylethyl)cyclopentyl]carbonyl]-3-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 787639-24-1 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-1-(1-methylethyl)-3-(1-pyrrolidinyl)cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-25-2 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-1-(1-methylethyl)-3-[3-(4-pyridinyl)-1-pyrrolidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-26-3 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-1-(1-methylethyl)-3-[3-(3-pyridinyl)-1-pyrrolidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-27-4 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-1-(1-methylethyl)-3-[3-(2-pyridinyl)-1-pyrrolidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-28-5 CAPLUS
CN 3-Pyrrolidineacetic acid, 1-[(3S)-3-[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-87-6 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-1-(1-methylethyl)-3-[4-(5-pyrimidinyl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-88-7 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-1-(1-methylethyl)-3-[4-(1H-tetrazol-1-yl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-89-8 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-1-(1-methylethyl)-3-[4-(1H-pyrazol-1-yl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-90-1 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-1-(1-methylethyl)-3-[4-(1H-1,2,3-triazol-1-yl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-91-2 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-1-(1-methylethyl)-3-[4-(1H-1,2,4-triazol-1-yl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-92-3 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-1-(1-methylethyl)-3-[4-(3H-pyrazol-3-yl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-93-4 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-1-(1-methylethyl)-3-[4-(5-methyl-2H-tetrazol-2-yl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-94-5 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-1-(1-methylethyl)-3-[4-(4-thiazolyl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-95-6 CAPLUS
CN Benzoic acid, 3-[1-[(3S)-3-[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]-4-piperidinyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-96-7 CAPLUS
CN Benzoic acid, 3-[1-[(3S)-3-[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]-4-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-97-8 CAPLUS
CN 1,6-Naphthyridine, 6-[[(1S)-3-[4-(2,5-dihydro-5-oxo-1,2,4-thiadiazol-3-yl)-1-piperidinyl]-1-(1-methylethyl)cyclopentyl]carbonyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-98-9 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-1-(1-methylethyl)-3-[3-(4-methyl-4H-1,2,4-triazol-3-yl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787639-99-0 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-1-(1-hydroxyethyl)-3-[4-(1H-1,2,4-triazol-1-yl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787640-00-0 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-1-(1-hydroxyethyl)-3-[4-(5-pyrimidinyl)-1-piperidinyl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787640-01-1 CAPLUS
CN 1,6-Naphthyridine, 6-[[(1S,3R)-3-[4-(4-fluorophenyl)-1-piperidinyl]-1-(methoxymethyl)cyclopentyl]carbonyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787640-02-2 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1R,3R)-3-(4-phenyl-1-piperidinyl)-1-(trifluoromethyl)cyclopentyl]carbonyl]-3-(trifluoromethyl)-, hydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●x HCl

RN 787640-54-4 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-1-(1-methylethyl)-3-(1-pyrrolidinyl)cyclopentyl]carbonyl]-3-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 791067-36-2 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[(1S)-1-(1-methylethyl)-3-[(4R,7S)-octahydro-4-methyl-4,7-epoxy-2H-isoindol-2-yl]cyclopentyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:802715 CAPLUS
DOCUMENT NUMBER: 141:314157
TITLE: Preparation of amino cyclobutylamide modulators of chemokine receptor activity
INVENTOR(S): Jiao, Richard; Yang, Lihu
PATENT ASSIGNEE(S): Merck & Co. Inc., USA
SOURCE: PCT Int. Appl., 108 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004082682	A1	20040930	WO 2004-US7792	20040315
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004222336	A1	20040930	AU 2004-222336	20040315
CA 2519220	A1	20040930	CA 2004-2519220	20040315
EP 1617841	A1	20060125	EP 2004-720791	20040315
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
CN 1787818	A	20060614	CN 2004-80013143	20040315
JP 2006520783	T	20060914	JP 2006-507176	20040315
IN 2005DN03929	A	20070824	IN 2005-DN3929	20050902
US 2006211722	A1	20060921	US 2005-549739	20050919
PRIORITY APPLN. INFO.:			US 2003-456047P P	20030318
			WO 2004-US7792 A	20040315

OTHER SOURCE(S): MARPAT 141:314157
GI



I



II

AB Title compds. represented by the formula I [wherein Z = independently C or N; R1 = H, heterocycle, Ph, cyano, etc.; R2-R4, R6 = independently H, (fluoro)alkyl, hydroxy, chloro, etc.; R5 = (fluoro)alkyl, (un)substituted pyridyl, bromo, etc.; R7-R9 = independently H, :O, Ph, (un)substituted alkyl; or R2R9 = heterocycle; A = (un)substituted amino or N-containing cyclic ring; and pharmaceutically acceptable salts and individual diastereomers thereof] were prepared as chemokine receptor modulators (no data). For example, II was given in a multi-step synthesis starting from the reaction of 3,5-bis(trifluoromethyl)benzylamine with 3-oxo-cyclobutanecarboxylic acid. Thus, I and their pharmaceutical compns. are useful as modulators of the chemokine receptor CCR-2 for the treatment of inflammatory and immunoregulatory disorders, and rheumatoid arthritis (no data).

IT 766513-12-6P 766513-14-8P 766513-16-0P
766513-18-2P 766513-20-6P 766513-22-8P
766513-24-0P 766513-57-9P 767332-04-7P
767332-05-8P 767332-06-9P 767332-07-0P
767332-08-1P 767332-09-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (piperidinyl)cyclobutylamide modulators of chemokine receptor activity)

RN 766513-12-6 CAPLUS

CN Cyclobutanecarboxamide, 1-(1-hydroxyethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-N-[[5-(trifluoromethyl)-3-pyridinyl]methyl]-, cis-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 766513-14-8 CAPLUS
CN Cyclobutanecarboxamide, 1-(1-methylethyl)-3-(4-phenyl-1-piperidinyl)-N-[[5-(trifluoromethyl)-3-pyridinyl]methyl]- (CA INDEX NAME)



RN 766513-16-0 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[1-(1-methylethyl)-3-(4-phenyl-1-piperidinyl)cyclobutyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 766513-18-2 CAPLUS
CN Cyclobutanecarboxamide, 1-(1-hydroxyethyl)-3-(4-phenyl-1-piperidinyl)-N-[[5-(trifluoromethyl)-3-pyridinyl]methyl]- (CA INDEX NAME)



RN 766513-20-6 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[1-(1-hydroxyethyl)-3-(4-phenyl-1-piperidinyl)cyclobutyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 766513-22-8 CAPLUS
CN Cyclobutanecarboxamide, 1-(1-hydroxy-1-methylethyl)-3-(4-phenyl-1-piperidinyl)-N-[[5-(trifluoromethyl)-3-pyridinyl]methyl]- (CA INDEX NAME)



RN 766513-24-0 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[1-(1-hydroxy-1-methylethyl)-3-(4-phenyl-1-piperidinyl)cyclobutyl]carbonyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 766513-57-9 CAPLUS
CN Cyclobutanecarboxamide, 1-(1-hydroxyethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-N-[[5-(trifluoromethyl)-3-pyridinyl]methyl]-, trans-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 767332-04-7 CAPLUS
CN Cyclobutanecarboxamide, 1-(1-methylethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-N-[[5-(trifluoromethyl)-3-pyridinyl]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 767332-05-8 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[1-(1-methylethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]cyclobutyl]carbonyl]-3-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 767332-06-9 CAPLUS
CN Cyclobutanecarboxamide, 1-(1-hydroxyethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-N-[[5-(trifluoromethyl)-3-pyridinyl]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 767332-07-0 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[1-(1-hydroxyethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]cyclobutyl]carbonyl]-3-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 767332-08-1 CAPLUS
CN Cyclobutanecarboxamide, 1-(1-hydroxy-1-methylethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-N-[[5-(trifluoromethyl)-3-pyridinyl]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 767332-09-2 CAPLUS
CN 1,6-Naphthyridine, 5,6,7,8-tetrahydro-6-[[1-(1-hydroxy-1-methylethyl)-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]cyclobutyl]carbonyl]-3-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:142517 CAPLUS
DOCUMENT NUMBER: 136:200102
TITLE: Preparation of N-cyclopentylpiperidines as modulators of chemokine receptor activity
INVENTOR(S): Yang, Lihu; Butora, Gabor; Parsons, William H.; Pasternak, Alexander
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 274 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002013824	A1	20020221	WO 2001-US25335	20010813
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2419194	A1	20020221	CA 2001-2419194	20010813
CA 2419194	C	20071016		
AU 2001083345	A	20020225	AU 2001-83345	20010813
EP 1318811	A1	20030618	EP 2001-962140	20010813
EP 1318811	B1	20060830		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004506013	T	20040226	JP 2002-518967	20010813
AT 337782	T	20060915	AT 2001-962140	20010813
ES 2271063	T3	20070416	ES 2001-962140	20010813
US 2002049222	A1	20020425	US 2001-931454	20010816
US 6545023	B2	20030408		

PRIORITY APPLN. INFO.: US 2000-225923P P 20000817
WO 2001-US25335 W 20010813
OTHER SOURCE(S): MARPAT 136:200102
GI



I



II

AB The title compds. I (R1 = H, (un)substituted C0-6alkyl-Y-C1-6alkyl and C0-6alkyl-Y-C0-6alkyl-C3-7cycloalkyl-C0-6alkyl wherein Y = bond, O, S, SO, SO2 and alkylamine; R2 = (un)substituted C0-6alkyl-Ph and C0-6alkyl-heterocycle; R3 = (un)substituted C0-6alkyl-phenyl; R4 = H, OH, alkyl, alkylhydroxy, CN, etc. or R3 and R4 may be joined to form a ring selected from 1H-indene, 2,3-dihydro-1H-indene, 1,3-dihydrobenzofuran, 1,3-dihydroisobenzofuran, 2,3-dihydrobenzothiofuran, and 1,3-dihydroisobenzothiofuran or R3 and R5 or R4 and R6 may be joined to form a (un)substituted Ph ring; R5 and R6 may also be independently selected from H, OH, alkyl, halo, etc.; X = NR7, O, CONR7, CH2O, NR7CO, CO2, OCO, CH2(NR7)CO, N(COR7) and CH2N(COR7) where R7 = H, (un)substituted -alkyl, -benzyl, -Ph, and -C1-6alkyl-C3-6cycloalkyl) are prepared and disclosed as modulators of chemokine receptor activity. Thus, II was prepared by ozonolysis of Et 3-methylenecyclopentane carboxylate, substitution with trans-3-methyl-4-(1,1-spiroindenyl)piperidine (preparation given), hydrolysis of intermediate Et spiropiperidinylmethylcyclpentane carboxylate and subsequent amidation by 3-trifluoromethyl-5-fluorobenzylamine. In particular, these compds. are useful as modulators of the chemokine receptor CCR-2 (no data). As chemokine receptor modulators, these compds. may be useful as anti-inflammatory and antirheumatic agents.

IT 400763-83-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of chemokine receptor modulators N-cyclopentylpiperidines useful as anti-inflammatory and antirheumatic agents)

RN 400763-83-9 CAPLUS

CN Cyclopentanecarboxamide, 1-methyl-3-[(1R,3'R)-3'-methylspiro[1H-indene-1,4'-piperidin]-1'-yl]-N-(3-pyridinylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d his

     (FILE 'HOME' ENTERED AT 12:49:22 ON 18 MAR 2008)

     FILE 'REGISTRY' ENTERED AT 12:49:32 ON 18 MAR 2008
L1             STRUCTURE UPLOADED
L2               1 S L1
L3             104 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 12:49:57 ON 18 MAR 2008
L4               7 S L3 FULL

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    38.63     217.20

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -5.60      -5.60

STN INTERNATIONAL LOGOFF AT 12:50:45 ON 18 MAR 2008
```